Publication Name	World Journal of Anesthesiology
Manuscript ID	5111
Country	Canada

Received	2013-08-16 08:12
Peer-Review Started	2013-08-16 10:39
To Make the First Decision	2013-09-02 16:13
Return for Revision	2013-09-04 16:49
Revised	2014-06-06 00:00
Second Decision	2014-06-16 13:59
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-06-16 14:11
Articles in Press	2014-06-16 14:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-08-18 21:37
Publish the Manuscript Online	2014-08-20 21:05

ISSN	2218-6182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Anesthesiology
Manuscript Type	Autobiography
Article Title	Paroxetine vs pregabalin for the management of neuropathic pain in multiple sclerosis
Manuscript Source	Invited Manuscript
All Author List	Dana A Turcotte, Malcolm Doupe, Mahmoud Torabi, Andrew J Gomori, Karen Ethans, Farid Esfahani, Katie Galloway and Michael P Namaka
Funding Agency and Grant Number
Corresponding Author	Dr. Dana A Turcotte, Faculty of Pharmacy, University of Manitoba, 750 McDermot Avenue, Winnipeg, Manitoba R3E 0T5, Canada. danaturcotte19@gmail.com
Key Words	Multiple sclerosis; Neuropathic pain; Paroxetine; Pregabalin; Clinical trial
Core Tip	The high attrition rates identified in the paroxetine study arm suggest that it be used with caution for multiple sclerosis (MS)-induced neuropathic pain (NPP). Although analysis of the primary endpoint measures revealed no significant differences, there was a trend toward marked improvement for visual analogue scale and daily impact of pain on daily activities in favor of pregabalin. However, due to the premature study cessation, definitive confirmation of pregabalin’s enhanced efficacy was not possible. These results reinforce the recognized challenges clinicians encounter in drug selection for MS-induced NPP. Due to the lack of well-designed controlled NPP trials in this population, effective and well-tolerated treatment selection poses a significant clinical challenge.
Publish Date	2014-08-20 21:05
Citation	Turcotte DA, Doupe M, Torabi M, Gomori AJ, Ethans K, Esfahani F, Galloway K, Namaka MP. Paroxetine vs pregabalin for the management of neuropathic pain in multiple sclerosis. World J Anesthesiol 2014; 3(2): 181-188
URL	http://www.wjgnet.com/2218-6182/full/v3/i2/181.htm
DOI	http://dx.doi.org/10.5313/wja.v3.i2.181

Full Article (PDF)	WJA-3-181.pdf
Full Article (Word)	WJA-3-181.doc
Manuscript File	5111-Review.docx
Answering Reviewers	5111-Answering reviewers.pdf
Copyright License Agreement	5111-Copyright assignment.pdf
Peer-review Report	5111-Peer review(s).pdf
Scientific Misconduct Check	5111-CrossCheck.jpg
Scientific Editor Work List	5111-Scientific editor work list.pdf